Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-05
1999-11-02
Fredman, Jeffrey
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 5, 435 6, 536 231, 536 243, 536 2431, 536 2432, 536 2433, 536 245, A61K 4800, C12Q 168, C07H 2104
Patent
active
059770830
ABSTRACT:
Oligodeoxyribonucleotides, polydeoxyribonucleotides and derivatives thereof, such as defibrotide, are agents of genetic modulation at the levels of transcription, translation, secondary messengers and cellular signal transduction systems. Various disease states can be treated by modifying the dose of such agents in response to observed fluctuations (e.g., increase, decrease, appearance, disappearance) in normal, disease and repair markers.
REFERENCES:
patent: 3770720 (1973-11-01), Butti
patent: 3829567 (1974-08-01), Butti
patent: 3899481 (1975-08-01), Butti
patent: 4374856 (1983-02-01), Ruwart
patent: 4649134 (1987-03-01), Bonomi
patent: 4693995 (1987-09-01), Prino
patent: 4795744 (1989-01-01), Carter
patent: 4938873 (1990-07-01), Rossi
Golboa et al. TIG 10: 139-144, 1994.
Orkin et al. Report and Reccomendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
Cook et al., "Effect of Reovirus Infection and Dietary Levels of Selected Vitamins on Immuoncompetence of Chickens," Chemical Abstract No. 99:52230p, 1983.
Ferro, "Possible Enhancement of Endothelial Cell Function Induced by Defibrotide," Chemical Abstract (1988), 109:104533m.
Girard et al., "Multivitamin for Treating Herpes Infections," Chemical Abstract No. 96:168754e, 1982.
Gendelman et al., "A Selective Defect of Interferon .alpha. Production in Human Immunodeficiency Virus-Infected Monocytes," Chemical Abstract No. 113:170225w, 1990.
Marni, "Protection of Kidney from Postischemic Reperfusion Injury in Rats Treated with Defibrotide," Chemical Abstract (1991), 114:55511v.
Merck Index 11th Ed., 1990, p. 192 (#1244-13 Biotin) and 449 (#2851--Defibrotide).
Oral et al., "Staphylococcal Protein--A Immunoadsorption (SPA) and Profabirnolytic Agent Defibrotide (D) Therapy of Thrombotic Microangiopathy," Blood, J. Amer. Soc. Hemat., Abstract 411a, Nov. 1989.
Wagner, "Applications of New Cyanine Labeling Reagents in Flow Cytometry," Abstracts for the XIV International Meeting of the Society for Analytical Cytology, Asheville, N.C., Mar. 18-23, 1990, 459A.
Berti, et al., "Opposite Effects of PGI.sub.2 and PAF Generated During Acute Myocardial Ischemia in the Perfused Rabbit Heart," Adv. Prost. Thromb. & Leuk. Res., 21:939-942 (1990).
Bilsel, et al., "Interaction of .sup.3 H-Defibrotide with Cultured Human Umbilical Vein Endothelial Cells," Thromb. Res., 58:455-460 (1990).
Bloom et al., "Tuberculosis: Commentary on a Reemergent Killer," Science, 257:1055-1064 (1992).
Bonomini, et al., "Effect of a New Antithrombotic Agent (Defibrotide) in Acute Renal Failure Due to Thrombotic Microangiopathy," Nephron, 40:195-200 (1985).
Bonomini, et al., "Use of Defibrotide in Renal Transplantation in Man," Haemostasis, 16:48-50 (1986).
Chaiet, et al., The Properties of Streptavidin, A Biotin-Binding Protein Produced by Streptomycetes, Arch. of Biochem. and Biophys., 106:1-5 (1964).
Cirillo, et al., "In vitro Inhibition by Defibrotide of Monocyte Superoxide Anion Generation: A Possible Mechanism for the Antithrombotic Effecti of a Polydeoxyribonucleotide-Derived Drug," Haemostasis, 21:98-105 (1991).
Cizmeci, et al, "In vivo Effects of Defibrotide on Platelet c-AMP and Blood Prostanoid Levels," Haemostasis, 16:31-35 (1986).
Coccheri, et al., "Effect on Fibronolysis of a New Antithrombotic Agent: Fraction P (Defibrotide). A Multicentre Trial," Int. J. Clin. Pharm. Res., 11:227-245 (1982).
Coccheri, et al., "Defibrotide," Cardiovascular Drug Rev., 9:172-196 (1991).
Colman, et al., "Antisense Strategies In Cell and Development Biology," J. Cell Science, 97:399-409 (1990).
Cornelli, et al., "Defibrotide: An Overview of Clinical Pharmacology and Early Clinical Studies," Seminars in Thromb. & Hemostasis, 14:64-70 (1988).
Costantini, et al., "Effects of Defibrotide on Prostanoid Synthesis and Fibrinolytic Activity in Human Veins," European J. of Internal Med., 1:115-120 (1989).
Dauber, et al., "Flow Cytometric Analysis of Lymphocyte Phenotypes in Bronchoalveolar Lavage Fluid," Dept. of Biological Science, The Mellon Institute, Carnegie-Mellon University, Pittsburgh, PA, (1991).
Fareed, et al., "Pharmacologic Validation of the Antithrombotic and Vascular Effects of Defibrotide," Adv. in Vascular Path., 171-177 (1990).
Fareed, et al., "Pharmacologic Profiling of Defibrotide in Experimental Models," Seminars in Thromb. and Hemostasis, 14:27-37 (1988).
Fauci, "Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," Science, 262:1011-1018 (1993).
Gao, "Mechanisms of Inhibition of Herpes Simplex Virus Type 2 Growth by 28-mer Phosphorothioate Oligodeoxycytidine," J. Biol. Chem., 265:20172-20178 (1990).
Green et al., "Optical Rotatory Dispersion, Circular Dichroism and Far-Ultraviolet Spectra of Avidin and Streptavidin," Biochem. J., 100:614-621 (1966).
Green, "Avidin," Adv. Prot. Chem., 29:85-133 (1975).
Gryglewski et al., "Prostacyclin and the Mechanism of Action of Defibrotide," Eicosanoids, 2:163-167 (1989).
Helene et al., "Specific Regulation of Gene Expression by Antisense, Sense and Antigene Nucleic Acids," Biochimica et Biophysica Aeta, 1049:99-125 (1990).
Horn et al., "Biotin-Mediated Delivery of Exogenous Macromolecules into Soybean Cells," Plant Physiol., 93:1492-1496 (1990).
Leonetti et al., "Intracellular Distribution of Microinjected Antisense Oligonucleotides," Proc. Natl. Acad. Sci., 88:2702-2706 (1991).
Leonetti et al., "Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates: Mechanism of Cell Uptake," Bioconjugate Chem., 1:149-153 (1990).
Lobel et al., "Selective Stimulation of Coronary Vascular PGI.sub.2 But Not of Platelet Thromboxane Formation by Defibrotide in the Platelet Perfused Heart," Naunyn-Schmiedeberg's Archives of Pharmacol., 331:125-130 (1985).
Loke et al., "Characterization of Oligonucleotide Transport Into Living Cells," Proc. Natl. Acad. Sci., 86:3474-3478 (1989).
Marni et al., "Protection of Kidney from Postischemic Reperfusion Injury in Rats Treated with Defibrotide," Transplantation Proceedings, 22:2226-2229 (1990).
McDougal et al., "Cellular Tropism of the Human Retrovirus HTLV-III/LAV," J. of Immunology, 135:3151-3162 (1985).
McDougal et al., "Immunoassay for the Detection and Quantitation of Infectious Human Retrovirus, Lymphadenopathy-Associated Virus (LAV)," J. Immunol. Methods, 76:171-183 (1985).
Miller et al., "Oligonucleotide Methylphosphonates as Antisense Reagents," Bio/Technology, 9:358-362 (1991).
Mitsuya et al., "Molecular Targets for AIDS Therapy," Science, 249:1533-1544 (1990).
Niada et al., "PGI.sub.2 -Generation and Antithrombotic Activity of Orally Administered Defibrotide," Pharmacological Res. COmm., 14:949-957 (1982).
Niada et al., "Antithrombotic Activity of a Polydeoxyribonucleotidic Substance Extracted From Mammalian Organs: A Possible Link with Prostacyclin," Thromb. Res., 23:233-246 (1981).
Niada et al., "Cardioprotective Effects of Defibrotide in Acute Lethal and Nonlethal Myocardial Ischemia in the Cat," Haemostasis, 16:18-25 (1986).
Nokta et al., "Human Immunodeficiency Virus Replication: Modulation by Cellular Levels of cAMP," AIDS Res. & Human Retrov., 8:1255-1261 (1992).
Orloff et al., "Penetration of CD4 T Cells by HIV-1: The CD4 Receptor Does Not Internalize with HIV, and CD4-Related Signal Transuction Events are not Required for Entry," J. Immunol., 146:2578-2587 (1991).
Pape et al., "Effect of Isonlazid Prophylaxis on Incidence of Active Tuberculosis and Progression of HIV Infection," Lancet, 342:268-272 (1993).
Pescador et al, "Pharmacokinetics of Defibrotide and of its Profibrinolytic Activity in the Rabbit," Thromb. Res., 30:1-11 (1983).
Ross, "Twists and Turns on G-Protein Signalling Pathways," Current Biol., 2:517-519 (1992).
Sabba et al., "A Pilot Evaluation of the Effect of Defibrotide in Patients Affected by Peripheral Arterial Occlusive Disease," Intl J. Clin. Pharm., Ther. & Toxic., 26:249-252 (1988).
Sarin et al., "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," Proc. Natl. Acad. Sci., 85:7448-7451 (1988).
Shea et al., "Synthesis, Hybridization Properties
LandOfFree
Method for using polynucleotides, oligonucleotides and derivativ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using polynucleotides, oligonucleotides and derivativ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using polynucleotides, oligonucleotides and derivativ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135570